Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares following this morning’s Q1 results. While the quarter was “not the best,” near-term catalysts warrant staying involved, including clinical updates for BIIB067 and BIIB098 head-to-head data versus Tecfidera expected in mid-2019, Raymond tells investors in a research note. Ahead of a Q4 regulatory decision for BIIB098, the analyst continues to like the upside potential for the pipeline. He keeps an Overweight rating on Biogen with a $280 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.